Jade Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
JBIO$15.60+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| September 30,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $50,106 | $69,386 |
| Investments | 148,799 | — |
| Prepaid expenses and other current assets | 2,455 | 268 |
| Total current assets | 201,360 | 69,654 |
| Property and equipment, net | 176 | — |
| Operating lease right-of-use asset | 740 | — |
| Other assets | 174 | 3,145 |
| Total assets | $202,450 | $72,799 |
| Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | 1,350 | 1,290 |
| Accrued expenses and other current liabilities | 14,012 | 4,125 |
| Related party accrued expenses and other current liabilities | 2,048 | 5,504 |
| Warrant liability, related party | 4,947 | 1,077 |
| Total current liabilities | 22,357 | 11,996 |
| Long-term liabilities: | ||
| Convertible Notes payable(1) | — | 107,600 |
| Long-term lease liability | 747 | — |
| Total liabilities | 23,104 | 119,596 |
| Commitments and contingencies (Note 13) | ||
| Series Seed convertible preferred stock, $0.0001 par value; no shares and 20,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; no shares and 20,000,000 issued and outstanding as of September 30, 2025 and December 31, 2024, respectively; liquidation preference of $2 as of December 31, 2024 and none as of September 30, 2025, respectively | — | 2 |
| Stockholders’ equity (deficit): | ||
| Series A non-voting convertible preferred stock, $0.0001 par value; 12,622 and no shares authorized as of September 30, 2025 and December 31, 2024, respectively; 12,622 shares and no shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 2 | — |
| Common stock, $0.0001 par value; 300,000,000 and 40,000,000 shares authorized as of September 30, 2025 and December 31, 2024, respectively; 32,626,730 and 3,672,794 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 3 | 1 |
| Additional paid-in capital | 321,769 | 179 |
| Accumulated other comprehensive income | 29 | — |
| Accumulated deficit | (142,457) | (46,979) |
| Total stockholders’ equity (deficit) | 179,346 | (46,799) |
| Total liabilities, Series Seed convertible preferred stock and stockholders' equity (deficit) | $202,450 | $72,799 |
(1)
Includes related party amount of $22.7 million at December 31, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.